By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Cima Labs, Inc. et al. v. Mylan Pharmaceuticals Inc.
1:10-cv-00117; filed July 28, 2010 in the Northern District of West Virginia
• Plaintiffs: Cima Labs, Inc.; Azur Pharma Ltd.; Azur Pharma International III Ltd.
• Defendant: Mylan Pharmaceuticals Inc.
Cima Labs Inc. et al. v. Mylan Pharmaceuticals Inc.
1:10-cv-00625; filed July 23, 2010 in the District Court of Delaware
• Plaintiffs: CIMA Labs Inc.; Azur Pharma Ltd.; Azur Pharma International III Ltd.
• Defendant: Mylan Pharmaceuticals Inc.
The complaints in these cases are substantially identical. Infringement of U.S. Patent Nos. 6,024,981 ("Rapidly Dissolving Robust Damage Form," issued February 15, 2000) and 6,221,392 (same title, issued April 24, 2001), licensed to Azur Pharma, following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Azur's FazaClo® (clozapine, used to treat schizophrenia). View the Delaware compliant here.
Takeda Pharmaceutical Co. et al. v. Wockhardt Ltd. et al.
1:10-cv-05699; filed July 28, 2010 in the Southern District of New York
• Plaintiffs: Takeda Pharmaceutical Co. Ltd.; Takeda Pharmaceuticals North America, Inc.
• Defendants: Wockhardt Ltd.; Wockhardt USA L.L.C.; Morton Grove Pharmaceuticals, Inc.
Infringement of U.S. Patent Nos. 5,965,584 ("Pharmaceutical Composition," issued October 12, 1999), 6,329,404 (same title, issued December 11, 2001), 6,166,043 (same title, issued December 26, 2000), 6,172,090 (same title, issued January 9, 2001), 6,211,205 (same title, issued April 3, 2001), 6,271,243 (same title, issued August 7, 2001), and 6,303,640 (same title, issued October 16, 2001) following a Paragraph IV certification as part of Wockhardt's filing of an ANDA to manufacture a generic version of Takeda's Actos® (pioglitazone hydrochloride, used to treat type II diabetes). View the complaint here.
Medicis Pharmaceutical Corp. v. Stiefel Laboratories, Inc.
5:10-cv-00621; filed July 28, 2010 in the Western District of Texas
Infringement of U.S. Patent No. RE41,134 ("Slow Release Vehicles for Minimizing Skin Irritancy of Topical Compositions," issued February 16, 2010) based on Stiefel's filing of an NDA to manufacture its Veltin product (antibiotic/retinoid gel), similar to Medicis' Ziana® (clindamycin phosphate and tretinoin gel, used to treat acne). View the complaint here.
Genzyme Corp. v. Roxane Laboratories Inc.
1:10-cv-00627; filed July 23, 2010 in the District Court of Delaware
Infringement of U.S. Patent No. 5,602,116 ("Method for Treating and Preventing Secondary Hyperparathyroidism," issued February 11, 1997) following a Paragraph IV certification as part of Roxane's filing of an ANDA to manufacture a generic version of Genzyme's Hectorol® (doxercalciferol, used to treat secondary hyperparathyroidism in patients with chronic kidney disease). View the complaint here.
Shire LLC v. Taro Pharmaceutical Industries Ltd. et al.
1:10-cv-05631; filed July 23, 2010 in the Southern District of New York
• Plaintiff: Shire LLC
• Defendants: Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals USA, Inc.
Infringement of U.S. Patent Nos. 5,326,570 ("Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine," issued July 5, 1994) and 5,912,013 (same title, issued June 15, 1999) following a Paragraph IV certification as part of Taro's filing of an ANDA to manufacture a generic version of Shire's Carbatrol® (carbamazepine, used to treat epilepsy and trigeminal neuralgia). View the complaint here.
APP Pharmaceuticals, LLC v. Navinta LLC et al.
3:10-cv-03708; filed July 22, 2010 in the District Court of New Jersey
• Plaintiff: APP Pharmaceuticals, LLC
• Defendants: Navinta LLC; Sandoz AG; Sandoz, Inc.; Hospira, Inc.; Sagent Pharmaceuticals, Inc.; Strides Inc.
Infringement of U.S. Patent Nos. 5,670,524 ("Methods and Compositions for the Treatment of Pain Utilizing Ropivacaine," issued September 23, 1997) and 5,834,489 (same title, issued November 10, 1998) following defendants' filing of an ANDA to manufacture a generic version of APP's Naropin® (ropivacaine hydrochloride injection product, used for the production of regional or local anesthesia for surgery and for acute pain management). View the complaint here.
Comments